My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Orencia Biosimilar Stable Cell Line

Orencia Biosimilar Stable Cell Line

Abatacept, CTLA-4 Fc Fusion Protein
Catalog No. Product Name Size List Price (US$) Quantity
C007 Orencia Biosimilar Stable Cell Line 1 package Request

Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.

The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

C007: Orencia Biosimilar Stable Cell Line (CHO)

The yield of Orencia biosimilar from the CHO stable cell line was above 2.1 g/L in a 15 liter manufacturing.

The Orencia biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following CTLA-4 Fc Fusion Protein biosimilar stable cell line:
Nulojix Biosimilar Stable Cell Line

Recombinant PD1 Protein:
Recombinant Human PD1-Fc Fusion Protein (IgG1)
Recombinant Human PD1-His Fusion Protein

Recombinant PDL1 Protein:
Recombinant Human PDL1-Fc Fusion Protein (IgG1)
Recombinant Human PDL1-FLAG Fusion Protein

Related Links

Super savings and terrific tips sent to your email inbox:

See our Privacy Policy